These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2945089)

  • 1. Solid state conformations and antidopaminergic effects of remoxipride hydrochloride and a closely related salicylamide, FLA 797, in relation to dopamine receptor models.
    Högberg T; Rämsby S; de Paulis T; Stensland B; Csöregh I; Wägner A
    Mol Pharmacol; 1986 Oct; 30(4):345-51. PubMed ID: 2945089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystallographic, theoretical and molecular modelling studies on the conformations of the salicylamide, raclopride, a selective dopamine-D2 antagonist.
    Högberg T; Norinder U; Rämsby S; Stensland B
    J Pharm Pharmacol; 1987 Oct; 39(10):787-96. PubMed ID: 2891816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and crystal structure of the hydrochloride monohydrate of (R)-N-[[1-(4-fluorobenzyl)-2-pyrrolidinyl]methyl]-5-bromo-2,3- dimethoxybenzamide, NCQ 115, a novel dopamine D2 receptor antagonist.
    Csöregh I; Högberg T
    Acta Pharm Nord; 1992; 4(1):1-4. PubMed ID: 1387534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
    Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
    Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide and related compounds. A comparative study.
    Högberg T; de Paulis T; Johansson L; Kumar Y; Hall H; Ogren SO
    J Med Chem; 1990 Aug; 33(8):2305-9. PubMed ID: 1973734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of dopamine D2-receptor selective antagonists.
    Högberg T
    Drug Des Discov; 1993; 9(3-4):333-50. PubMed ID: 8400011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners.
    Högberg T; Ström P; de Paulis T; Stensland B; Csöregh I; Lundin K; Hall H; Ogren SO
    J Med Chem; 1991 Mar; 34(3):948-55. PubMed ID: 1672158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remoxipride shows low propensity to block functional striatal dopamine D2 receptors in vitro.
    Westlind-Danielsson A; Gustafsson K; Andersson I
    Eur J Pharmacol; 1994 Dec; 288(1):89-95. PubMed ID: 7705472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular structure and absolute configuration of the hydrochloride of a novel dopamine receptor antagonist: 2S(-)-5-chloro-3-ethyl-N-[(1-ethyl-2-pyrrolidinyl) methyl]-6-methoxysalicylamide.
    Wägner A; Stensland B; Csöregh I; de Paulis T
    Acta Pharm Suec; 1985; 22(2):101-10. PubMed ID: 4050456
    [No Abstract]   [Full Text] [Related]  

  • 10. Conformationally restricted analogues of remoxipride as potential antipsychotic agents.
    Norman MH; Kelley JL; Hollingsworth EB
    J Med Chem; 1993 Oct; 36(22):3417-23. PubMed ID: 7901417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QSAR modeling on dopamine D2 receptor binding affinity of 6-methoxy benzamides.
    Samanta S; Debnath B; Gayen S; Ghosh B; Basu A; Srikanth K; Jha T
    Farmaco; 2005 Oct; 60(10):818-25. PubMed ID: 16055122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular structures of metabolites and analogues of diethylstilbestrol and their relationship to receptor binding and biological activity.
    Duax WL; Swenson DC; Strong PD; Korach KS; McLachlan J; Metzler M
    Mol Pharmacol; 1984 Nov; 26(3):520-5. PubMed ID: 6548545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative structure-activity relationships of salicylamide neuroleptic agents.
    Gupta SP; Saha RN; Singh P
    Drug Des Deliv; 1990 May; 6(1):41-7. PubMed ID: 1981828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational analysis of dopamine D-2 receptor antagonists of the benzamide series in relation to a recently proposed D-2 receptor-interaction model.
    Pettersson I; Liljefors T
    J Med Chem; 1992 Jun; 35(13):2355-63. PubMed ID: 1535660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
    Johansson E; Parkinson GN; Denny WA; Neidle S
    J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of oxidation-reduction potentials in flavodoxin from Clostridium beijerinckii: the role of conformation changes.
    Ludwig ML; Pattridge KA; Metzger AL; Dixon MM; Eren M; Feng Y; Swenson RP
    Biochemistry; 1997 Feb; 36(6):1259-80. PubMed ID: 9063874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quantitative structure-activity relationship for some dopamine D2 antagonists of benzamide type.
    Norinder U; Högberg T
    Acta Pharm Nord; 1992; 4(2):73-8. PubMed ID: 1388772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G; Rogóz Z; Wieczorek A
    Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.